Synfacts, Table of Contents Synfacts 2023; 19(06): 0615DOI: 10.1055/s-0042-1752682 Innovative Drug Discovery and Development Discovery of a Selective pan-FGFR Inhibitor Approved for Treatment of Cholangiocarcinoma Contributor(s): Antonia F. Stepan (Roche) , Danica A. Rankic (Pfizer) Recommend Article Abstract Buy Article Key words Key wordsfutibatinib - pan-FGFR inhibitor - covalent drug - cholangiocarcinoma - hit-to-lead Full Text